Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

Published:2014 Issue:2 Volume:3 Page:67-69
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Dao Kim-Hien T.,Solti Magdolna B.,Maxson Julia E.,Winton Elliott F.,Press Richard D.,Druker Brian J.,Tyner Jeffrey W.

Funder

OHSU Knight Cancer Institute

National Institutes of Health, National Heart, Lung and Blood Institute

Howard Hughes Medical Institute

V Foundation for Cancer Research

Leukemia and Lymphoma Society

Gabrielle׳s Angel Foundation for Cancer Research

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference8 articles.

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (IARC WHO Classification of Tumours),2008

2. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment;Gotlib;Blood,2013

3. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML;Maxson;N Engl J Med,2013

4. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia;Pardanani;Leukemia,2013

5. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis;Mascarenhas;Clin Cancer Res,2012

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management;American Journal of Hematology;2024-04-21

2. Atypical CML: diagnosis and treatment;Hematology;2023-12-08

3. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms;Cancers;2023-07-27

4. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes;Blood Advances;2023-04-26

5. Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia;Leukemia Research Reports;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3